Comparative Pharmacology
Head-to-head clinical analysis: HC HYDROCORTISONE versus HEXADROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC HYDROCORTISONE versus HEXADROL.
HC (HYDROCORTISONE) vs HEXADROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis; suppresses inflammatory cytokine production; and causes vasoconstriction and immunosuppression.
Synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to regulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
Hydrocortisone 100-500 mg IV/IM every 2-6 hours as needed for acute adrenal insufficiency or severe inflammation. Maintenance: 20-30 mg/day PO divided every 8-12 hours.
Adult: 0.75-9 mg/day orally in divided doses every 6-12 hours; IV/IM: initial 0.5-9 mg/day in divided doses every 6-12 hours.
None Documented
None Documented
1.5–2.5 hours (terminal half-life). In clinical context, the biological half-life (duration of HPA suppression) is longer (8–12 hours) due to tissue binding and active metabolites.
Terminal elimination half-life: 36-54 hours; prolonged in hepatic impairment (up to 72 hours) due to reduced clearance.
Renal: predominantly as conjugated metabolites and a small fraction of unchanged drug. Biliary/fecal: minor, <5%. Total renal clearance accounts for >95% of elimination.
Primarily renal: ~65-80% as unchanged drug and metabolites via glomerular filtration, with tubular reabsorption; minor biliary/fecal (5-10%).
Category D/X
Category C
Corticosteroid
Corticosteroid